{"title":"支持酮症酸中毒依赖性肿瘤的致癌Krebs循环酶突变","authors":"M. Israël","doi":"10.31579/2640-1045/089","DOIUrl":null,"url":null,"abstract":"Tumors incorporate much glucose for overcoming glycolytic pyruvate-kinase and pyruvate-dehydrogenase inhibitions; they form lactate, rather than oxidative acetyl-CoA. Tumors also need to synthetize fatty acids, which automatically turns-off their mitochondrial degradation into acetyl-CoA. Thus, ketolysis becomes their major acetyl-CoA supply. Carcinogenic mutations or deficiencies of Krebs-cycle enzymes support the ketolytic dependency of tumors.","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Carcinogenic Krebs-Cycle Enzyme Mutations Supporting Ketolytic-Dependent Tumors\",\"authors\":\"M. Israël\",\"doi\":\"10.31579/2640-1045/089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Tumors incorporate much glucose for overcoming glycolytic pyruvate-kinase and pyruvate-dehydrogenase inhibitions; they form lactate, rather than oxidative acetyl-CoA. Tumors also need to synthetize fatty acids, which automatically turns-off their mitochondrial degradation into acetyl-CoA. Thus, ketolysis becomes their major acetyl-CoA supply. Carcinogenic mutations or deficiencies of Krebs-cycle enzymes support the ketolytic dependency of tumors.\",\"PeriodicalId\":72909,\"journal\":{\"name\":\"Endocrinology and disorders : open access\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinology and disorders : open access\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31579/2640-1045/089\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology and disorders : open access","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31579/2640-1045/089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Tumors incorporate much glucose for overcoming glycolytic pyruvate-kinase and pyruvate-dehydrogenase inhibitions; they form lactate, rather than oxidative acetyl-CoA. Tumors also need to synthetize fatty acids, which automatically turns-off their mitochondrial degradation into acetyl-CoA. Thus, ketolysis becomes their major acetyl-CoA supply. Carcinogenic mutations or deficiencies of Krebs-cycle enzymes support the ketolytic dependency of tumors.